The sodium glucose co-transporter-2 inhibitor empagliflozin is part of a larger class of drugs being tested for their ability to reduce blood glucose levels in Type 2 diabetic adults by blocking the kidneys from reabsorbing high-glucose urine.
"We are excited to have submitted an application for a potential new treatment option that may help patients better manage their Type 2 diabetes mellitus," said Dr. Christophe Arbet-Engels, Boehringer Ingelheim's VP of metabolic-clinical development and affairs. "Type 2 diabetes mellitus is a critical health issue facing the world today, and through the Boehringer Ingelheim and Lilly Diabetes Alliance, we are committed to developing new treatments to address patients with this disease."
The class of drugs is currently part of 12 multinational clinical trials and is in phase 3 clinical trials with the FDA. Looking ahead, Eli Lilly and Boehringer Ingelheim expect to release results of these studies throughout 2013 and 2014.
According to Eli Lilly, Type 2 diabetes accounts for 90% of all diabetes cases worldwide,and resulted in approximately $245 billion of medical costs and lost productivity in 2012.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Find out which big American pharma is best suited to provide big gains in the years to come.
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Worry about whether drug pricing will return to the forefront in Washington, D.C. is increasing following Donald Trump's nomination of a drug-industry insider as his next Department of Health and Human Services secretary.